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S U M M A R Y
A case of disseminated nocardiosis caused by Nocardia elegans in a 72-year-old man with rheumatoid
arthritis, treated with tacrolimus and prednisolone, is reported herein. The patient had impaired vision
and was diagnosed with endophthalmitis and an abdominal skin abscess. He was started on
trimethoprim–sulfamethoxazole treatment, followed by cefepime. The patient was then switched to a
combination of imipenem–cilastatin and minocycline. Although the patient survived as a result of
surgery and prolonged antibiotic treatment, he eventually lost vision after the infection became resistant
to antibiotic treatment. Molecular analysis of samples from the abscess and vitreous ﬂuid conﬁrmed the
extremely rare pathogen N. elegans, which accounts for only 0.3–0.6% of infections caused by Nocardia
species. This organism is almost always associated with pulmonary infection, and disseminated
infections are rare. As with previously reported norcardial infections, the current case was treated
successfully with trimethoprim–sulfamethoxazole, carbapenems, and aminoglycosides. However, the
clinical characteristics of this organism remain unclear. Further studies are therefore required to develop
more effective treatment protocols for disseminated nocardiosis caused by this problematic pathogen.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Nocardia species are Gram-positive aerobic actinomycetes that
are ubiquitous in soil and water. They can cause local (pulmonary
nocardiosis) or disseminated (systemic/disseminated nocardiosis)
infection in humans, and readily cause infection in immunocom-
promised patients with autoimmune disease or those undergoing
treatment with steroids or immunosuppressive agents. Recent
reports suggest that the incidence of nocardiosis is increasing,1–4[5_TD$DIFF]
and that it is a life-threatening infectious disease. The number of
Nocardia species described has been expanding rapidly; there are
currently more than 100 species. Although there are differences
in the distribution of Nocardia species worldwide, N. asteroides,
N. farcinica,N. nova,N. transvalensis,N. brasiliensis,N. abscessus, and
N. cyriacigeorgica are the most common.1–3,5 In addition, each
Nocardia species displays a different clinical spectrum.
In contrast, Nocardia elegans accounts for less than 1% of
infections caused by Nocardia species. Since the ﬁrst case of N.
elegans infection was reported by Yassin and Brenner in 2005,6* Corresponding author. Tel.: +81 3 3342 6111; fax: +81 3 5339 3817.
E-mail address: task300@tokyo-med.ac.jp (I. Nakamura).
http://dx.doi.org/10.1016/j.ijid.2016.10.031
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).only a few other cases have been reported. Although almost all of
these previous cases in humans have been associated with
pulmonary infections, a case of disseminated nocardiosis caused
by N. elegans in a patient undergoing immunosuppressive therapy
is presented herein. The clinical signiﬁcance of Nocardia species
remains unclear because of the variety of organisms causing
infection. Therefore, a new case of disseminated nocardiosis is
presented and previous cases of N. elegans infection are reviewed.
2. Case report
A 72-year-old man undergoing tacrolimus (1.5mg/day) and
prednisolone (10 mg/day) treatment for rheumatoid arthritis was
admitted to the hospital suffering from pneumonia. A chest X-ray
showed consolidation in the upper lobe of the right lung, and a
2-week course of ceftriaxone was started upon admission without
sputum culture. A computed tomography (CT) scan of the chest
obtained approximately 3 weeks post-admission revealed gradual
improvement of the infection. However, 1 week post-discharge,
the patient was again admitted to the hospital with a 2-day history
of recurrent episodes of eye pain and impaired vision. He was
diagnosed with endophthalmitis. Blood tests indicated an elevated
white blood cell count (12.9  109/l), high levels of C-reactiveciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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0.02 mg/ml). Chest CT again showed consolidation in the upper
lobe of the right lung, and cefepime (2 g/day) was administered for
5 days. In addition, voriconazole (200 mg/2 days) and ﬂuconazole
(100 mg/day) were administered for 3 and 5 days, respectively,
because high b-D-glucan levels (32.6 pg/ml) indicated a fungal
infection. As the causative agent of the endophthalmitis appeared
to be resistant to antibiotic treatment, a vitrectomy was
performed; however, neither the eye pain nor the impaired vision
improved.
During the treatment of endophthalmitis, swelling and warmth
in the abdominal wall was diagnosed as a subcutaneous abscess. A
specimen was obtained following drainage of the abscess, and
bacteriological examination identiﬁed Nocardia species. Based on
drug susceptibility analysis, trimethoprim–sulfamethoxazole (ST)
treatment (10 mg/kg, as trimethoprim) was started. However,
drug-induced kidney injury was detected 7 days after the onset of
ST treatment, necessitating a change of therapy to a combination of
imipenem–cilastatin (IPM–CS, 0.5 g every 12 h) and minomycin
(MINO, 100 mg every 12 h). The abdominal abscess improved
following antibiotic treatment. However, a right-side ophthal-
mectomy was performed 1 month after the initiation of antibiotic
therapy following treatment failure of IPM–CS and MINO and
worsening of the endophthalmitis.
After 6 weeks of IPM–CS administration, treatment was
changed to MINO monotherapy. However, because of observed
liver dysfunction during MINO administration, clarithromycin
therapy (CAM, 200 mg every 12 h) was ﬁnally selected. Long-term
CAM therapy has been in place for 20 months without relapse.
Gram staining of bacteria isolated from the abscess and vitreous
ﬂuid samples revealed Gram-positive rods that formed an
extensively branched substrate mycelium. Kinyoun staining
indicated that cells had a thin, acid-fast cell wall. Following
aerobic incubation at 35 8C for 3 days on 5% sheep blood agar,
white colonies with a wrinkled surface were observed. The
identities of the clinical isolates were conﬁrmed by 16S rRNA
gene sequencing analysis, as described previously.4 Susceptibility
testing was performed using the broth microdilution method,
according to the guidelines of the Clinical and Laboratory
Standards Institute. The results of susceptibility testing carried
out pre-treatment and at 1-month post-treatment are shown in
Table 1. Molecular analysis conﬁrmed that the isolates from bothTable 1
Susceptibility testing of the Nocardia elegans strain isolated in the current case, pre-
and post-therapy
Agent MICa Interpretationb MICc Interpretationb
AMPC/CVA >32/16 R >32/16 R
CTRX <2 S 4 S
CTX <2 S 4 S
CFPM <1 S 2 S
IPM <0.5 S <0.5 S
LZD <1 S 2 S
AMK <0.5 S <0.5 S
TOB >16 R >16 R
CFPX 4 R >4 R
MINO 1 S 2 I
DOXY 4 I 8 R
CAM <0.25 S <0.25 S
ST 19/1 S 38/2 S
MIC, minimum inhibitory concentration (mg/ml); AMPC/CVA, amoxicillin clavu-
lanate; CTRX, ceftriaxone; CTX, cefotaxime; CPFX, [3_TD$DIFF]ciproﬂoxacin; CFPM, cefepime;
IPM, imipenem; LZD, linezolid; AMK, amikacin; TOB, tobramycin; CFPX,; MINO,
minocycline; DOXY, doxycycline; CAM, clarithromycin; ST, trimethoprim–sulfa-
methoxazole.
a Analysis of the strain isolated pre-antibiotic treatment.
b Interpretation according to Clinical and Laboratory Standards Institute
guidelines: S, susceptible; I, intermediate; R, resistant.
c Analysis of the isolate following 2 months of antibiotic treatment.the abdominal wall abscess and vitreous body samples were N.
elegans.
3. Literature review
3.1. Methods
To identify previously reported cases of N. elegans infection, the
PubMed database was searched using the search words ‘‘Nocardia
elegans’’ and ‘‘N. elegans’’. In addition, the references cited in
previously published reports were also reviewed. To compare the
more common Nocardia species with N. elegans, the incidence and
treatment protocols for all Nocardia species were also searched.
3.2. Incidence of N. elegans
Recent reports have shown that the incidence of infection caused by
Nocardia species is increasing.1–4 However, trends in the incidence
of N. elegans infection are less clear because of the rarity of this
disease. Only seven cases of nocardiosis caused by N. elegans have
been reported to date.2,6–11 In general, N. elegans is very rarely
isolated and accounts for only 0.3–0.6% of infections caused by
Nocardia species.2,10,12 Previous reports on the epidemiology of
nocardiosis have not included any cases caused by N. elegans.1,3–5
Therefore, the incidence of N. elegans infection is presumed to be
very low.
3.3. Clinical spectrum of N. elegans
A literature review indicated that the most common sites/types
of nocardial infection are pulmonary (39%), systemic/disseminated
(32%), extrapulmonary (12%), and central nervous system (9%).13
Interestingly, N. elegans is almost always associated with pulmo-
nary infection, with only one casewithout pulmonary involvement
(purulent arthritis) reported to date. However, rare cases of severe
disseminated infection do occur (Table 2). The ﬁrst report of
disseminated infection caused by N. elegans was published in
2014,11 and the current case appears to be only the second
reported case.
Nocardiosis infection appears to occur in patients with
underlying disease or who are undergoing treatment with an
immunosuppressive agent. In the current case, the patient had
rheumatoid arthritis and was being treated with steroid and
immunosuppressive therapies. Although previous reports on N.
elegans infection provide little information on underlying condi-
tions, half of the cases had connective tissue disease.
3.4. Identiﬁcation of N. elegans
As traditional identiﬁcationmethods are not particularly useful
for Nocardia species because of limited biochemical and physio-
logical differences between organisms, molecular techniques are
more frequently used.5 In particular, 16S rRNA gene identiﬁcation
has greatly expanded the number of recorded Nocardia species and
is used widely for the identiﬁcation of N.elegans.1,2,4,6,9,11,12 In
addition, matrix-assisted laser desorption/ionization time-of-
ﬂight mass spectrometry (MALDI-TOF MS) is reported to have
potential for the identiﬁcation of N.elegans.8,14
3.5. Antimicrobial susceptibility and antimicrobial treatment of
N. elegans
Because Nocardia species differ in clinical spectrum and
susceptibility to antibiotics, it is important to identify Nocardia
isolates precisely, beyond the genus level. Increasing resistance of
Nocardia species to ST has been problematic, with resistance rates
Table 2
Clinical characteristics and outcomes of Nocardia elegans infections in the current case and in seven previously published cases
No. [Ref.] Age, years Sex Sitea[2_TD$DIFF] Type Treatmentb Outcome
16 - - P Local - -
22 46 F P Local - -
37 26 M P Local MEPM+TOB -
48 73 M P Local IPM+AMK Improved
59 66 F J Local - -
610 51 M P Local ST Improved
711 69 M P+B Disseminated ST+CAM Improved
Case 73 M P+E+S Disseminated ST! IPM+MINO!CAM Improved with ophthalmectomy
F, female; M, male; ‘-’, unknown.
a P, pulmonary; J, joint; B, brain; E, eye; S, skin.
b MEPM, meropenem; TOB, tobramycin; IPM, imipenem–cilastatin; AMK, amikacin; ST, trimethoprim–sulfamethoxazole; CAM, clarithromycin; MINO, minocycline[1_TD$DIFF].
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generation cephalosporin amikacin (AMK), and MINO are key
antibiotics used for the treatment of nocardiosis. A previous study
indicated that IPM–CS, AMK, linezolid (LZD), and daptomycin had
the lowest minimum inhibitory concentration (MIC90) values for
the unusual Nocardia species.12
The antibiotic susceptibility ofN. elegans in previous reports has
mainly been determined using the broth microdilution method, as
recommended by the Clinical and Laboratory Standards Institute
(document M24-A). Some reports regarding the antibiotic
susceptibility of N. elegans show in vivo susceptibility to ST,
IPM–CS, CAM, MINO, and LZD.2,6–9 Although previous studies have
provided little information on the response to antimicrobial
treatment, ST, carbapenems, aminoglycosides, and CAM have been
used to successfully treat nocardial infections (Table 2). Impor-
tantly, resistance to ST was only seen in one case.8 These
antimicrobial agents were also selected based on susceptibility
analysis in the present case; however, drug toxicity and resistance
during therapy meant that treatment was ceased. In addition,
decreasing susceptibility to other antimicrobial agents was
observed during treatment. Therefore, further reports on appro-
priate antimicrobial treatment are needed.
4. Summary
The clinical characteristics, diagnostic methods, antimicrobial
susceptibility, and optimal treatment protocols for N. elegans
remain unclear because of the small number of reported cases.
Further studies are therefore required to develop more effective
treatment protocols for disseminated nocardiosis caused by this
problematic pathogen.
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